Medicine Name: Oncovet I (Imatinib 100 mg)
Imatinib Mesylate 119,5 mg - Tablets.
Package: 3 blister containing 10 pills each (30 tablets).
Chemotherapy drug to canine and feline with cancer.
Use in veterinary medicine
Made in Argentina
Description: Chemotherapy for dogs and cats. Composition: Imatinib: 100 mg Excipients authorized. 278 mg c.s.p.
Action: Tirosin Kinase Inhibitor.
Indications: Treatment of cancer patients such as mast cell tumor, fibrosarcomas, gastrointestinal stromal tumors, hemangiosarcomas, B-cell leukemia, meningiomas in canines and mastocytomas, sarcomas associated with vaccines and hypereosinophilic syndrome in felines. Also in pulmonary arterial hypertension in canines.
Antineoplastic effect in dogs: 10 mg / kg / day. Minimum and maximum dose: 4.4 - 12.7 mg / kg / day.
Pulmonary arterial hypertension in dogs: 3 mg / kg / day.
Dose interval: It must be calculated by the veterinary oncologist, according to certain variables of the histopathological study, other complementary studies and clinical stage of the animal with cancer. In general, 1 dose is administered every 24 hours. If complete remissions are achieved, it can be administered every 48 hours.
Number of administrations: The amount of time that must be calculated by the veterinary oncologist, according to certain variables such as: clinical stage of the animal with cancer, results of the histopathological study, other complementary studies and diseases or conditions of the animal concomitantly. It should be administered once a day until complete remission of the disease is achieved. If this is not observed at least a partial remission in less than 40 days, the chemotherapeutic protocol should be changed.
If a satisfactory objective response is observed, it should be administered for life, but daily evaluating that the clinical benefits in the patient are superior to the collateral effects and the progression of the oncological disease.
Therapeutic regimen: The interval and numbers of cycles should be indicated by a diplomate veterinary oncology. General rule is daily.
Precautions to be taken before, during and after administration: Handling: Imatinib is classified as a non-aggressive cytostatic according to its tissue aggressiveness. The drug Oncovet C contains Imatinib in coated tablets. The person who administers does not require protection from exposure unless the tablets are broken or fragmented. The procedures destined to a correct manipulation and elimination of the anticarcinogenic drugs should be considered. Several informative guidelines have already been published in this regard. In case of irritation during handling, it is recommended to wash with water and soap for 10-15 minutes. It is recommended that pregnant women do not handle the medication. If they are required to do so, it is recommended that they wear latex or nitrile gloves. The stool of the animal (fecal matter, urine, saliva or vomit) should also be cleaned using latex or nitrile gloves for 48 hours after the last administration. Oncovet I must be administered directly orally. It should be used judiciously and with constant monitoring in patients with renal and / or hepatic insufficiency. It is recommended to respect the indicated indications, administration mode and posology. Do not use or store near drinks, food, medicines, household and fire products. Keep in a dry and cool place, protected from sunlight and far from the reach of children and pets. Most adverse reactions are reversible if they are detected early. When such adverse effects or reactions occur, the dose of the drug should be reduced or the treatment discontinued and the appropriate corrective measures adopted at the veterinarian's discretion. Liver and kidney function tests before starting treatment and then every 3-4 weeks.
Interactions with Other Drugs: The following drug interactions have been documented or are theoretically possible in animals receiving cyclophosphamide: Allopurinol: May increase myelosuppression caused by cyclophosphamide. Cardiotoxic drugs (for example, Doxorubicin). Use cautiously when using cyclophosphamide together with other cardiotoxic agents since potentiation of this effect may occur. Chloramphenicol: May inhibit the metabolism of cyclophosphamide. Imipramine: May inhibit the metabolism of cyclophosphamide. Phenobarbital (or other barbiturates): The administration of these drugs for a long time increases the speed of the metabolism of cyclophosphamide to active metabolites through the process of microsomal enzymatic induction and increases the possibility of development of toxicity. Phenothiazines: They can inhibit the metabolism of cyclophosphamide. Potassium iodide: May inhibit the metabolism of cyclophosphamide. Succinylcholine: Metabolism can be slowed down with the resulting prolongation of effects, since cyclophosphamide can lower levels of circulating pseudocholinesterase. Diuretics derived from thiazides: May increase myelosuppression caused by cyclophosphamide. Vitamin A: It can inhibit the metabolism of cyclophosphamide. The levels of uric acid (in blood and urine) may increase after administering cyclophosphamide. The immunosuppressive properties of cyclophosphamide can cause false negative results in skin tests with a variety of antigens, including tuberculin, candida and trichophyton.
Concerns and Cautions: As with all chemotherapy agents, Imatinib should not be used in pregnancy, lactation, or in animals to be used for breeding. Live vaccinations should not be given while the patient is on Imatinib.